Trials / Completed
CompletedNCT02477670
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Comparison Design (SPCD) Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- Avanir Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVP-786 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-07-21
- Completion
- 2017-07-21
- First posted
- 2015-06-23
- Last updated
- 2020-09-16
- Results posted
- 2020-09-16
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02477670. Inclusion in this directory is not an endorsement.